Insider buying last 90 days
No open-market insider purchases were filed for CON in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Concentra Group Holdings Parent reported Q3 2026 results this week, with revenue up 8.6% year-over-year to $622.1 million, net income up 36% to $67.8 million, and Adjusted EBITDA growing 17.9% to $140.2 million, driven by patient visit growth. Adjusted earnings of $0.52 per share topped estimates, and the company raised its 2026 revenue and adjusted earnings outlook, citing favorable labor conditions and market share gains. Alongside the results, several Form 4 filings showed director William Keith Newton, CEO Matthew DiCanio, and executive Michael D. Rhine each having shares withheld at $40.90 to cover taxes on restricted stock vesting, transactions tied to administrative tax obligations rather than open-market sales.
CON closed at $42.40, up 0.4%, sitting above both its 50-day average of $37.16 and 200-day average of $29.10, with the 50-day above the 200-day. The stock's one-month return stands at 14%, its three-month return at 28.4%, and its one-year return at 126.6%, with the 52-week range spanning $18.89 to $44.22. The GekkoIndex reads 48.4, placing the stock in the Neutral zone, while price sits 6.4% above the Gekko Fair Value of $39.86.
The next earnings date falls on 25 February 2027, outside the typical 20-trading-day holding window, with the prior report on 6 August 2026 producing a 10.7% reaction. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, and no billionaire holders are recorded. Analyst coverage from 4 firms is unanimously rated buy, with a consensus target of $42 implying -0.9% upside from current levels, a gap worth noting alongside the premium to fair value.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Concentra Group Holdings Parent scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
Above 50 and 200-day
Close $42.55 is above the 50-day ($37.87) and 200-day ($29.52) averages, and the 50-day is above the 200-day.
See the chart52, Neutral
Reading 52 is in the Neutral zone.
See the GekkoIndex5.4% above
Price is 5.4% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Concentra Group Holdings Parent closed at $42.55 on Nov 13, 2026, +113.2% over the past year, inside a 52-week range of $18.96 to $44.22.
Use the left and right arrow keys to read daily values.
Put CON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Concentra Group Holdings Parent runs health services aimed at people hurt or affected on the job, serving businesses across the United States. Its offerings span care for workplace injuries, walk-in urgent treatment, lab and imaging testing, checkups meant to catch problems early, and programs built around what individual employers need, plus efforts to keep workers well overall. Patients get to these services through a set of clinics dedicated to occupational care and locations placed directly at employer worksites, which has made the company a familiar name in this space.
The company also runs a few more targeted offerings. Concentra Telemed lets people get remote care for job-related injuries and illnesses while giving employers extra support options. Concentra Pharmacy handles medication needs, and Concentra Medical Compliance Administration acts as an outside manager for employer drug testing programs, covering both workforces under regulation and those without such requirements. Its clients are largely companies looking to handle health and testing obligations for their staff, and the firm sits under Select Medical Corporation as a subsidiary.
The company traces back to 1979 and runs its operations from Mechanicsburg, Pennsylvania. Shares trade on the NYSE under the ticker CON.
Concentra Group Holdings Parent’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, up 4.6 points over five sessions.
Up 4.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 10 | +3.7% | +1.1% | ||
| Accumulation | 200 | +0.4% | +2.7% | ||
| Neutral (current zone) | 286 | +0.6% | +2.4% | ||
| Distribution | 72 | +1.0% | +1.4% | ||
| Selling | 2 | Too few readings yet | |||
Average CON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Concentra Group Holdings Parent trades 5.4% above Gekko Fair Value of $40.37, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Concentra Group Holdings Parent shares are worth, recalculated every trading day.
$40.37
Gekko Fair Value, Nov 14, 2026
5.4% Overvalued
At the end of Aug 2026 the price was 11.9% below the estimate.
No open-market insider purchases were filed for Concentra Group Holdings Parent, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CON in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CON were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Concentra Group Holdings Parent has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold CON.
Concentra Group Holdings Parent reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
Expected after the close, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.52 est $0.42 | $606.0M est $591.7M | +10.7% |
| May 7, 2026 | $0.40 est $0.34 | $569.6M est $553.5M | +5.9% |
| Jan 28, 2026 | $0.28 est $0.23 | $539.1M est $532.1M | −0.3% |
| Nov 6, 2025 | $0.39 est $0.38 | $572.8M est $532.0M | +1.0% |
| Aug 7, 2025 | $0.37 est $0.37 | $550.8M est $537.4M | +8.4% |
| May 7, 2025 | $0.32 est $0.32 | $500.8M est $496.1M | −2.7% |
| Mar 3, 2025 | $0.17 est $0.17 | $465.0M est $486.6M | −0.6% |
| Oct 31, 2024 | $0.37 est $0.36 | $489.6M est $492.6M | −3.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Concentra Group Holdings Parent is $45.90, +7.9% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Wells Fargo | $48 | +12.8% |
| Nov 10 | RBC Capital | $49 | +15.2% |
| Nov 9 | Stephens | $51 | +19.9% |
| Nov 9 | Mizuho Securities | $47 | +10.5% |
| Nov 9 | Jefferies | $50 | +17.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Concentra Group Holdings Parent’s market cap is $5.38B, with a P/E ratio of 25.4 and revenue of $2.34B over the last twelve months.
Coverage of Concentra Group Holdings Parent this week reads neutral: 4 positive, 11 neutral and 0 negative headlines.
Concentra Group Holdings Parent’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
A peer links to its own page where one exists.
Concentra Group Holdings Parent’s market cap is $5.38B at the Nov 13, 2026 close of $42.55, with 125.7M shares outstanding. The shares trade on a P/E ratio of 25.4.
The consensus analyst 12-month price target for Concentra Group Holdings Parent is $45.90, +7.9% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Concentra Group Holdings Parent is overvalued: the Nov 13, 2026 close of $42.55 is 5.4% above Gekko Fair Value of $40.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Concentra Group Holdings Parent is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of $0.29 per share on revenue of $573.4M. Concentra Group Holdings Parent beat the earnings estimate in 5 of its last 8 reports, moving 4.1% on average across the report.
Concentra Group Holdings Parent’s 52-week high is $44.22 and its 52-week low is $18.96; it closed at $42.55 on Nov 13, 2026, +113.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.